Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene's Hybrid Capture II

This article was originally published in The Gray Sheet

Executive Summary

Human papillomavirus test is more accurate than conventional Pap smear screening for identifying women with cervical disease, according to a study published in the Sept. 10 British Journal of Cancer and reported by Digene Sept. 13. The test was sufficiently sensitive to detect 95% of women with serious cervical disease while less than 5% of normal women tested positive, researchers found. In comparison, the Pap smear was able to detect only 79% of those with cervical disease. Conducted in the U.K. by the Imperial Cancer Research Fund, the study included 2,988 women over 35 who were given the HPV test and Pap screening simultaneously. The Hybrid Capture II was approved by FDA in March for use as an adjunct to the Pap smear for cervical cancer screening. Investigators suggest the findings support use of the test for primary screening

You may also be interested in...



ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel